Nevro Corp. (NVRO) News
Filter NVRO News Items
NVRO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVRO News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NVRO News From Around the Web
Below are the latest news stories about NEVRO CORP that investors may wish to consider to help them evaluate NVRO as an investment opportunity.
What Makes Nevro (NVRO) a New Buy StockNevro (NVRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Nevro price target lowered to $4.70 from $7 at TruistTruist lowered the firm’s price target on Nevro (NVRO) to $4.70 from $7 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance sheets, an |
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on December 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,000 shares of Nevro's common stock to 20 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan a |
Here's Why you Should Retain Nevro Stock in Your Portfolio NowNVRO's continued technological innovations and business diversification plans raise optimism about the stock. |
Zacks.com featured highlights include Stryve Foods, Nevro, Canoo, MSA Safety and VTEXStryve Foods, Nevro, Canoo, MSA Safety and VTEX have been highlighted in this Screen of The Week article. |
Bet on 5 Top-Ranked Stocks With Rising P/ETap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Stryve Foods, Nevro, Canoo, MSA Safety and VTEX. |
US Penny Stocks To Watch In November 2024As the U.S. stock market experiences a resurgence, with major indexes on track for weekly gains and Bitcoin reaching new all-time highs, investors are exploring diverse opportunities to capitalize on these trends. Penny stocks, often representing smaller or newer companies, remain an intriguing option despite their historical connotations. They can offer a unique blend of value and growth potential when supported by strong financial fundamentals, presenting investors with promising avenues... |
NVRO Stock Declines Despite Positive Study Data of Nevro1 SystemNevro unveils publication of positive data study regarding its Nevro1 SI Joint Fusion System. |
Inside a $400 billion bet on the brain-computer interface revolutionMorgan Stanley's latest report pegs the BCI market at $400 billion — signaling to investors that this revolutionary technology is the next big bet in medtech. |
New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral ApproachesNevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1™ SI Joint Fusion System ("Nevro1"), a posterior integrated transfixation cage system offering enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindrical threa |